医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Biotechnology Industry Organization (BIO) and the China Center for Pharmaceutical International Exchange (CCPIE) Announce Strategic Partnership to Expand the BIO Convention in China

2013年04月19日 AM05:10
このエントリーをはてなブックマークに追加


 

WASHINGTON

The world’s largest biotechnology trade association, BIO, and CCPIE, an independent, public institution affiliated with the China Food and Drug Administration (CFDA), today announced a strategic partnership to expand the BIO Convention in China, an annual conference that brings together 1,000 executives from global biotech and pharmaceutical companies interested in exploring business development, networking and deal making opportunities.

Now in its third year, the BIO Convention in China has established itself as the exclusive forum for the industry’s elite to develop strategic collaborations, establish distribution networks, find service providers and create cross-border alliances with companies from the U.S., Europe and Asia.

“China has set the stage for strong growth of biotech within its borders and made growing the biotech industry one of its top national priorities. The BIO Convention in China promotes partnering and deal making discussions that will open up opportunities for companies to expand throughout Asia,” said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development. “CCPIE is an ideal co-host for this annual event and shares BIO’s mission to support and encourage innovation and investment to help biotech flourish in China.”

“BIO has demonstrated their commitment to international exchange and cooperation with China’s pharmaceutical and emerging biotech sectors,” said Zhao Yajun, Director-General of CCPIE. “CCPIE is pleased to serve as a co-host for this year’s BIO Convention in China, a must attend partnering event for those seeking in and out-licensing opportunities with multinational corporations.”

“This strategic partnership with CCPIE will also serve to further our policy engagement in China, where BIO supports the development of a therapeutic biologics industry that ensures better access to innovative and quality medicines for patients in China. With the help of CCPIE, we will continue to engage with CFDA, and other ministries, to serve as a trusted partner and expert on the industry,” said Joseph Damond, Senior Vice President, International Affairs.

Since its foundation in 1989, CCPIE has carried out extensive foreign exchanges and cooperation through private channels, and established cooperative relationships with non-governmental institutions, academic institutions and consulting agencies from more than 20 countries and regions. The center includes the following departments: Division of General Affairs; Division of Technological Cooperation; Division of Consultancy Services and Division of Conference & Exhibition.

The 2013 BIO Convention in China dates and location will be announced at the 2013 BIO International Convention taking place April 22-25, 2013, in Chicago.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO International Convention
April 22 – 25, 2013
Chicago, IL

World Congress on Industrial Biotechnology
June 16-19, 2013
Montreal, Canada

BIO IPCC Conference
November 6-8, 2013
Washington, DC

Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 8-11, 2013
San Diego, CA

CONTACT

Biotechnology Industry Organization (BIO)
Abigail Hirsch,
202-962-9230
Web: www.bio.org
Blog:
www.biotech-now.org
Twitter:
@IAmBiotech

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作